SAN FRANCISCO, Oct. 27 Nile Therapeutics, Inc.,(Nasdaq: NLTX), announced today that Peter Strumph, Chief Executive Officer,will present at the 7th Annual BIO Investor Forum on Thursday, October 30th,at 9:00 a.m. PT at The Palace Hotel in San Francisco.
Mr. Strumph will provide an overview of Nile and an update on its clinicaldevelopment programs, including interim data from Nile's Phase 2a study forits lead compound, CD-NP, a novel chimeric peptide for the treatment of heartfailure.
The presentation will be webcast live and can be accessed by visiting theInvestor Relations section of Nile's website at http://www.nilethera.com. Thewebcast will be archived for 90 days.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company thatdevelops innovative products for the treatment of cardiovascular disease andother areas of unmet medical need. Nile is initially focusing its efforts ondeveloping its lead compound, CD-NP, a novel rationally designed chimericpeptide in clinical studies for the treatment of heart failure; 2NTX-99, asmall molecule, pre-clinical, anti-atherothrombotic agent with nitric oxidedonating properties; and CU-NP, a novel rationally designed natriureticpeptide. A key component of the company's strategy is to acquire the globalrights to additional compounds to expand its portfolio. More information onNile can be found at http://www.nilethera.com.
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 that involvesubstantial risks and uncertainties. All statements, other than statements ofhistorical facts, included in this press release regarding our strategy,future operations, outlook, milestones, the success of Nile's productdevelopment, future financial position, future financial results, plans andobjectives of management are forward-looking statements. We may not actuallyachieve these plans, intentions or expectations and Nile cautions investorsnot to place undue reliance on our forward-looking statements. Actual resultsor events could differ materially from the plans, intentions and expectationsdisclosed in the forward-looking statements we make. Various important factorsthat could cause actual results or events to differ materially from theforward-looking statements that we make are described in greater detail in thereports we file with Securities and Exchange Commission, including the "RiskFactors" section in Item 1 of the Form 10-KSB we filed with the Securities andExchange Commission on March 27, 2008. Nile is providing this information asof the date of this press release and does not undertake any obligation toupdate any forward-looking statements as a result of new information, futureevents or otherwise.
SOURCE Nile Therapeutics, Inc.